Corvus Pharmaceuticals, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Corvus Pharmaceuticals, Inc. (CRVS) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $11.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-12
- Corvus Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $11.60M, a 52.63% increase from fiscal 2024.
- Corvus Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $7.60M, a 15.15% increase from fiscal 2023.
- Corvus Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $6.60M, a 28.26% decline from fiscal 2022.
- Corvus Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $9.20M, a 19.30% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $11.60M 10-K · filed 2026-03-12 | |
| 2024-12-31 | $7.60M 10-K · filed 2026-03-12 | |
| 2023-12-31 | $6.60M 10-K · filed 2025-03-25 | |
| 2022-12-31 | $9.20M 10-K · filed 2025-03-25 | |
| 2021-12-31 | $11.40M 10-K · filed 2023-03-28 | |
| 2020-12-31 | $11.40M 10-K · filed 2022-03-10 | $1.50M 10-K · filed 2021-03-25 |
| 2019-12-31 | $1.50M 10-K · filed 2022-03-10 | $13.00M 10-K · filed 2020-03-09 |
| 2018-12-31 | $19.40M 10-K · filed 2020-03-09 | |
| 2017-12-31 | $9.10M 10-K · filed 2019-03-07 | |
| 2016-12-31 | $7.00M 10-K · filed 2018-03-01 | |
| 2015-12-31 | $5.80M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |